ClinicalTrials.gg
RecruitingNCT05283850SPEARUpdated Mar 17, 2022

Surviving PEA in Roanoke (SPEAR) Study

A Phase 2/3 interventional study of High Calcium, Low Sodium (HCLS) Crystalloid Therapy and High Calcium, High Sodium (HCHS) Crystalloid Therapy in Cardiac Arrest and Pulseless Electrical Activity, sponsored by Carol Bernier. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by Carol Bernier · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
342
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 171 studies in Heart Arrest with a site in United States — 40 open to participants now, 45 under way, 2 of them phase 3. Heart Arrest · United States.

Planned enrollment
34th of 117
342 · median 72
Started
2022
with 4 others
Phase 2/3
4 of 171
1 open now
Primary completion
2027-02
later than 7 of 44 live
Registered
123rd of 171
by date

Among the 171 studies in Heart Arrest with a site in United States, this one is the 34th largest by planned enrollment of the 117 interventional ones that give a count, is one of 5 that started in 2022, is one of 4 in phase 2/3, reaches primary completion later than 7 of the 44 other live ones, and was the 123rd registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

40 of the 171 studies in Heart Arrest with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 171 studies in Heart Arrest with a site in United States, or all of them as a file.
02

Study summary

The Carilion Clinic and Virginia Tech Carilion School of Medicine, in conjunction with Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and Salem Fire-EMS, are studying the outcomes of patients experiencing Pulseless Electrical Activity (PEA). PEA refers to a type of cardiac arrest in which there is normal electrical activity in the heart however the heart still fails to contract to generate a pulse. Without heart contractions, which normally generates a pulse, the brain and other important organs fail to receive blood and oxygen. Unfortunately, the majority (97.3%) of patients that experience this rhythm do not survive and most don't even make it to the hospital. This study is trying to determine if the administration of a High Calcium, Low Sodium (HCLS) fluid in pre-hospital care will improve the chances of survival.

Generally, a sodium (salt) solution is provided to patients experiencing cardiac arrest. Studies have shown that lower sodium and higher calcium content may activate certain parts of the heart cells required to generate a pulse under PEA conditions.

This study is a double-blind, prospective, clinical trial. PEA patients will randomly receive either routine fluid therapy (salt solution) or a HCLS solution. While HCLS solution is not the standard fluid used by EMS providers responding to PEA, it is composed of FDA approved components and is occasionally used by EMS providers at their discretion in treating PEA. It is predicted that HCLS will either improve PEA survival or deliver similar outcomes as routine treatment. All patients will receive standard, high quality cardiac arrest and post-cardiac arrest care regardless of assigned treatment group.

Read the detailed description

Pursuant to a Waiver of Informed Consent, this investigation will automatically enroll all eligible PEA patients treated by Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and/or Salem Fire-EMS systems.

Once patients are enrolled, they will be de-facto randomized into one of two groups: control High Calcium-High Sodium (HCHS) or interventional High Calcium-Low Sodium (HCLS). Supervisors will have on their trucks, numbered-but-otherwise-blinded bags of half-normal saline or normal saline solution. The bags will be numbered, recorded and randomized by this study's investigators. Supervisors, when providing care, will universally administer 1g unblinded CaCl2 and then subsequently chose a crystalloid fluid set to use from their trucks randomly. The crystalloid will be administered as a wide open IV drip at a rate of at least 1000ml/hour, depending on gauge size, for as long as fluids are indicated for, likely resulting in a crystalloid dose of 0.5-2(L) liters. Each bag-set will have two bags of the same blinded unit to allow for treatment with up to (2L) 2 liters of fluid for a patient. Explicitly, all enrolled patients will be receiving calcium, it is only the crystalloid fluid (normal saline vs half-normal saline) that will differ. HCLS treatment was designed to be hyponatremic compared to normal saline (while both groups in this trial will be hypercalcemic compared to pure normal saline PEA therapy) in order to initiate low sodium inotropy.

The contents of the bag will be blinded to the supervisor. Neither the patient nor the supervisor will know which treatment was given thus ensuring double-blinding. Further, by randomly choosing a bag with no knowledge of its contents, the treatment will effectively be randomized. Both groups will otherwise receive current routine Advanced Cardiac Life Support and either standard post-arrest care or standard termination of care. Per Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and Salem Fire-EMS standard protocol, only patients who undergo ROSC on scene will be transported to a hospital.

03

Conditions studied

  • Cardiac Arrest
  • Pulseless Electrical Activity

Browse trials for

Keywords

  • Crystalloid Fluids
  • Emergency Medical Services (EMS)
  • Pre-Hospital Medicine
  • Sodium Chloride
  • Calcium Chloride
  • Normal Saline
  • Half-Normal Saline
  • Waiver of Informed Consent
  • Paramedic
  • Electrolyte
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All patients who present with PEA at any time during the patients' treatment by Roanoke Fire-EMS, Botetourt County Department of Fire \& EMS and/or Salem Fire-EMS. This study defines a PEA presentation as any patient who is unconscious, presenting without a carotid pulse and with non-(VT/VF) ventricular tachycardia/ventricular fibrillation electrical activity.

Exclusion criteria

Exclusion Criteria:

  • Patient less than 18 years old
  • Known pregnancy
  • Duration of untreated cardiac arrest of more than 30 minutes
  • Traumatic cardiac arrest
  • Known (LVAD) Left Ventricular Assist Device
  • Rapidly fatal underlying disease
  • Known or suspected digitalis toxicity
  • A physical, durable (DNR) Do Not Resuscitate (or durable DNR medical jewelry) presented to EMS before treatment with asserting a preference not to be enrolled
  • Prisoners and other populations with involuntary consent
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
342 participants (estimated)

Study arms

  • Active comparator
    High-Calcium, High- Sodium (HCHS) group

    Patients will receive a drip of blinded, intravenous, normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.

    Drug: High Calcium, High Sodium (HCHS) Crystalloid Therapy

  • Experimental
    High-Calcium, Low- Sodium (HCLS) group

    Patients will receive a drip of blinded, intravenous, half-normal saline and an unblinded, intravenous, one gram bolus of calcium chloride.

    Drug: High Calcium, Low Sodium (HCLS) Crystalloid Therapy

Interventions

  • DrugHigh Calcium, Low Sodium (HCLS) Crystalloid Therapy

    Half-normal saline IV drip and 1g IV bolus Calcium Chloride.

    Also known as: (NDC) National Drug Code NDC 0264-7800-00 and NDC 0409-4928-11

  • DrugHigh Calcium, High Sodium (HCHS) Crystalloid Therapy

    Normal saline IV drip and 1g IV bolus Calcium Chloride.

    Also known as: NDC NDC 0264-7802-00 and NDC 0409-4928-11

06

What researchers measure

Primary outcomes

  1. Event Survival

    ROSC sustained until arrival at the emergency department and transfer of care to medical staff at the receiving hospital?

    Time frame: Up to 1 hour

Secondary outcomes

  1. Any Return-Of-Spontaneous-Circulation (ROSC)

    Did the patient achieve ROSC at any point during the resuscitation attempt?

    Time frame: Through resuscitation efforts up to 1 hour after arrival to (ED) Emergency Department

  2. Survival to hospital discharge

    Did the patient survive to hospital discharge?

    Time frame: Up to 30 days after admission to (ED) Emergency Department

  3. Neurological outcome at hospital discharge

    (CPC) Cerebral Performance Category Score and/or (mRS) modified Rankin Score at hospital discharge?

    Time frame: Up to 30 days after admission to ED

  4. Serum Electrolyte Values

    All (BMP) Basic Metabolic Panel values will be collected, but there is a particular emphasis on serum sodium and calcium values.

    Time frame: Up to 12 hour after admission to the (ED) Emergency Department

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Unidentified data could be arranged to be shared with researchers who specifically request it, but this study is not currently (IRB) Institutional Review Board approved to do so.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Feb 2027, 60 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2022
First posted
Mar 17, 2022
StartActual
Feb 16, 2022
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05283850
Lead sponsor
Carol Bernier
Responsible party
Carol Bernier (Assistant Professor of Emergency Medicine, Carilion Clinic) — Sponsor-investigator
First posted
Mar 17, 2022
Start date
Feb 16, 2022
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Mar 17, 2022

Study contacts

Cara Spivy, MS
Contact
crspivey@carilionclinic.org
540-676-7965
William Reis, MS
Contact
wrreis@carilionclinic.org
Carol Bernier, DO
principal investigator · Virginia Polytechnic Institute and State University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion